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Background: PKC412 (N-benzoyl-staurosporine), an oral inhibitor of protein kinase C, is capable of cell
cycle inhibition and is endowed with anti-angiogenic properties. This dose-finding phase I study was designed
to establish the maximum tolerated dose (MTD) of PKC412 when combined with cisplatin–gemcitabine.
Patients and methods: Escalating doses of PKC412 were given every day of a 4 week cycle with cisplatin
100 mg/m2 on day 2 and gemcitabine 1000 mg/m2 on days 1, 8 and 15 in patients with non-small-cell lung
cancer. Dose escalation was based on a modified continuous reassessment method.
Results: Twenty-three patients, assigned to four cohorts receiving PKC412 at a dose ranging from 25 to
150 mg/day were evaluable. Grade 3 diarrhea occurring in 3/4 patients at cycle 1 led us to define 150 mg/day as
the MTD. The MTD based on multiple cycles was redefined as 100 mg/day, since prolonged grade 2–3 nausea/
vomiting leading to treatment discontinuation occurred in 3/7 patients after repeated cycles. The next lower
dose tested of 50 mg/day was therefore considered as the recommended dose for phase II trials. Among
33 cycles in eight patients, toxicity consisted of grade 1–2 diarrhea (12.5%) and asthenia (50%) with only one
patient experiencing grade 3 headache at this dose level. A partial response was observed in three patients.
Conclusions: The results of the present study indicate that PKC412 at a dose of 50 mg/day can be safely added
to cisplatin and gemcitabine in patients with advanced non-small-cell lung cancer.
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Introduction
Protein kinase C (PKC) belongs to a family of serine-threonine
kinases involved in several signaling pathways [1]. The PKC
enzyme family comprises more than 12 isoenzymes which can be
classified into the following three main groups: (a) conventional
calcium- and diacylglycerol (DAG)-dependent PKCs-α, -β and
-γ; (b) calcium-independent but DAG-dependent PKCs-δ, -ε, -η
and -θ; and (c) calcium-independent and DAG-unresponsive
PKCs-ζ and -ι [1, 2]. PKC isoenzymes play key roles in the
up- and down-regulation of the G1–S and G2–M cell cycle check-
points, but also in apoptosis, angiogenesis, differentiation, invasion,
senescence and drug efflux [3]. PKCs also act as secondary
messengers in the mitogenic signaling pathway of platelet-derived
growth factor (PDGF) and vascular endothelial growth factor
(VEGF) [4, 5]. Most non-small-cell lung cancer (NSCLC) cell
lines express high PDGF and PDGF-R (PDGF-receptor) mRNA
levels [6], while PDGF-Rs are highly expressed in endothelial
cells in and around tumors [7]. VEGF overexpression also carries
a poor prognosis in resected NSCLC [8] and targeting VEGF
pathways downstream might also be a way of preventing tumor
growth [9]. PKC inhibitors have been investigated for the treat-
ment of cancer due to their capacity to modulate the cell cycle and
angiogenesis [1]. Two indolocarbazole staurosporine analogues,
UCN-01 (7-hydroxy-staurosporine) and PKC412 (N-benzoyl-
staurosporine) (Figure 1), which compete for binding to the ATP site
on PKCs, as well as ISIS-3521, an antisense oligodeoxynucleotide
that inhibits PKC-α mRNA, have been included in clinical trials
[10–12].
PKC412 interacts strongly with ATP binding sites of the
conventional PKCs-α, -β and -γ, PDGF-Rβ, VEGF-R2, VEGF-R1
and the cyclin-dependant kinase 1–cyclin B complex. At the cellular
level, inhibition of the conventional PKCs-α, -β and -γ by
PKC412 [1] leads to inactivation of the mitogen-activated protein
kinase pathway induced by tumor promoting phobol esters and
ultimately affects c-fos expression [13]. In human T98 glioblast-
oma cells, exposure to PKC412 decreases cdk1/cdk2 kinase activ-
ity [14], blocks the cell cycle at the G2–M boundary and induces
apoptosis [15]. In addition, PKC412 has been demonstrated to
elicit anti-angiogenic effects by inhibiting PDGF-R and VEGF-R
expression in mice implanted with a porous teflon chamber con-
taining VEGF [13, 16]. The antitumor activity of PKC412 in nude
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mice bearing human H460 NSCLC tumor xenografts was found to
be significantly higher than that observed with a number of con-
ventional cytotoxic agents, including doxorubicin, cyclophos-
phamide, cisplatin and gemcitabine [15]. No sequence dependent
toxicity was reported from animal experiments. In a phase I study
in patients with advanced cancer, oral PKC412 was given daily at
doses ranging from 12.5 to 300 mg [11]. No hematological toxic-
ities were reported. Dose-limiting toxicities (DLT) consisted of
nausea/vomiting, diarrhea, headache and lethargy/fatigue. In that
trial, no formal maximum tolerated dose (MTD) could be estab-
lished even though grade 2–3 non-hematological toxicities in
more than half of the patients prohibited higher doses (225 and
300 mg/day) for chronic oral administration. The recommended
dose (RD) of single agent PKC412 was 150 mg/day. The median
elimination half-life of PKC412 was 1.6 days. The steady
state plasma PKC412 levels at the RD were in the range of con-
centrations associated with cytotoxicity in cancer cell lines (114–
399 ng/ml). Human α1-acidic glycoprotein (AAG) binds strongly
(99%) to PKC412 and still more firmly (99.9%) to its two major
active metabolites (CGP62221 and CGP52421) [15]. A partial
response and one case of disease stabilization lasting 4.5 months
have been reported.
Based on single agent activity of PKC412 in NSCLC and the
additive effects evidenced in vitro with cisplatin [15], a phase I
study was designed using a cisplatin–gemcitabine regimen with
escalating doses of PKC412. The primary objective was to deter-
mine the MTD of PKC412 combined with cisplatin and gemcitabine.
Secondary objectives were as follows: (a) to define the DLT
of PKC412 when combined with cisplatin–gemcitabine; (b) to
establish the RD of PKC412 when combined with chemotherapy
containing cisplatin–gemcitabine; (c) to characterize the phar-
macokinetic (PK) profile of PKC412 at the RD; and (d) to report
evidence for anti-tumor activity in patients with NSCLC.
Patients and methods
Eligibility criteria
Patients with histologically-proven stage IIIB–IV NSCLC who were suitable
for cisplatin and gemcitabine chemotherapy were eligible for entry onto the
study. Other eligibility criteria were as follows: age ≥18 years; World Health
Organization (WHO) performance status <2; life expectancy ≥3 months; no
chemotherapy or investigational agent administered during the previous 28 days
(40 days for mitomycin C, nitrosoureas or immunotherapy); no major surgery
or radiotherapy during the previous 28 days; no evidence of brain metastases;
no concurrent malignancy (except basal cell carcinoma and in situ cervical
cancer); no active infection and no other severe concomitant illness. Women
who were pregnant, breast feeding, or adults of reproductive potential without
an effective birth control method at least 1 week prior to treatment were
excluded; an effective contraception method was recommended for the overall
duration of treatment and for at least 6 months post-treatment.
Eligible patients fulfilled the following criteria for study entry: neutrophil
count, ≥1.5 × 109/l; hemoglobin ≥10 g/dl; platelet count ≥100 × 109/l; serum
creatinine <1.5 × upper limit of normal (ULN); and total bilirubin <1.5 × ULN
with serum aspartate aminotransferase and alanine aminotransferase levels
<2.0 × ULN.
All patients gave their written informed consent before treatment according
to institutional and national guidelines. The study was performed according to
French and Swedish drug regulations and complied with the principles of the
Helsinki Declaration. The protocol was approved by the University of Kremlin-
Bicêtre (France) and the University of Umea (Sweden) Ethics Committees.
The present analysis is based on the examination of the source case report
forms by the participating investigators who had access to all study data.
Study design
Before entry onto the study, all patients were required to have a clinical
history, physical examination, chest and abdominal computed tomography
(CT) scan, complete blood work-up comprising complete blood count and
serum chemistries (sodium, potassium, calcium, creatinine, urea, bilirubin,
aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase,
lactate dehydrogenase and total protein) and an electrocardiogram. During
Figure 1. Structure of staurosporine, UCN-01 (7-hydroxystaurosporine), PKC412 (N-benzoyl-staurosporine), CGP62221 and CGP52421-epimer. Adapted 
from Fabbro et al. [15] and Senderowicz and Sausville [30].
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treatment, a medical history, toxicity assessment and complete blood work-up
were performed weekly. Toxicity grading was performed in accordance with
the National Cancer Institute–common toxicity criteria (NCI–CTC), version
2.0 [17]. Patients were evaluated for tumor response every two cycles. Stand-
ard Southwest Oncology Group (SWOG) criteria were used to determine
response [18]. Criteria for withdrawing patients from the study included tumor
progression, dose-limiting or unacceptable toxicity as determined by the treat-
ing physician and patient refusal.
Drug administration
PKC412 was supplied by Novartis (Basel, Switzerland) in soft gelatin cap-
sules containing 25 mg of the active drug substance. Capsules were taken with
water during or following meals. The first dose of PKC412 was taken before
administering chemotherapy. PKC412 was given orally daily during a 28-day
cycle without interruption during and between cycles. Scheduled dose levels
were 25 mg (25 mg taken o.d.), 50 mg (25 mg taken b.i.d.), 75 mg (25 mg taken
t.i.d.), 100 mg (50 mg taken b.i.d.), 150 mg (50 mg taken t.i.d.) and 225 mg
(75 mg taken t.i.d.). Fractionation of the daily doses was empirically chosen to
improve the digestive tolerability and to reduce the number of pills that needed
to be swallowed at one time. Dosage of PKC412 was reduced by 50% at cycle
two in case of grade 3–4 PKC412-related toxicities.
On days 1, 8 and 15, gemcitabine 1000 mg/m2 diluted in 100 ml of 0.9%
NaCl was given as a 30-min intravenous infusion 1 h after the administration
of PKC412. Antiemetic treatment before gemcitabine consisted of ondan-
setron 8 mg and methylprednisolone 125 mg. On day 2, cisplatin 100 mg/m2
diluted in 250 ml of 0.9% NaCl was given intravenously over 60 min and
hydration with 3 l 0.9% NaCl, 1 h after the administration of PKC412. Anti-
emetic treatment during cisplatin therapy consisted of ondansetron 8 mg per os
twice to three times daily, that was continued, in case of prolonged nausea,
with dexamethasone 20 mg with or without bromazepam 1 mg four times daily
for 2 days. In case of prolonged nausea 2 days after cisplatin therapy, the anti-
emetic regimen was intensified with prednisone 100 mg and metoclopramide
40 mg [19].
Gemcitabine dose was adjusted in case of hematological toxicity. If grade 2
neutropenia and/or thrombocytopenia occurred at day 8 and/or 15, 75% of the
initial gemcitabine dose was given. If grade 3 or 4 neutropenia and/or thrombo-
cytopenia occurred at days 8 and/or 15, gemcitabine was omitted and a
decrease of 25% was made at the subsequent cycle. The next cycle was delayed
until hematological recovery. Dose adjustments for non-hematological toxic-
ities were as follows: a 50% decrease in the initial gemcitabine dose was
recommended in case of grade 3–4 transaminase elevation at day 8 and/or 15.
A 50% decrease in the cisplatin dose was recommended in case of grade 1
nephrotoxicity and no cisplatin was given until recovery if nephrotoxicity
exceeded grade >1. Cisplatin was discontinued when grade 3 neurotoxicity
and grade 2 ototoxicity occurred.
Dose escalation procedure
The starting dose of PKC412 was 25 mg daily, i.e. 1/6 of the recommended
dose of single agent PKC412 established in the phase I study [11]. A modified
continual reassessment method (MCRM) was used for dose escalation [20].
For dose-finding purposes, four patients were assigned sequentially to each
cohort. The daily PKC412 dose increments foreseen, namely 25, 50, 75, 100,
150 and 225 mg, were based on a single agent phase I study [11].
DLTs were defined as grade 4 neutropenia lasting at least 7 days, grade 4
febrile neutropenia, grade 4 thrombocytopenia, grade ≥2 nephrotoxicity and
any other grade 3–4 non-hematological toxicity (excepted alopecia and acute
nausea/vomiting). Nausea/vomiting occurring during the first week of treat-
ment were considered as acute and cisplatin related, while nausea/vomiting
lasting >1 week and disappearing after discontinuation of PKC412 were
considered as prolonged and PKC related. Prolonged nausea/vomiting that
persisted for >1 week, despite an adapted anti-emetic regimen, and any other
toxicity that required dose reduction or treatment discontinuation were con-
sidered as DLT.
Dose escalation was primarily designed to define the MTD based on acute
DLT of PKC412 when combined with cisplatin and gemcitabine during cycle
1 of treatment. The MTD was defined as the highest dose of PKC412 at which
>35% of the patient population would experience DLT during cycle 1. The
DLT observed after treatment of each cohort of patients was noted and the
dose-toxicity model defined by the MCRM was updated accordingly. If no
DLT was observed in a group of four patients, then the dose escalation pro-
ceeded to a further dose level. If one of four patients experienced DLT at cycle 1,
then four new patients had to be entered at this dose level. In that situation,
dose escalation was allowed to resume to a further dose level if three or less
patients of eight experienced DLT at cycle 1. The probability of DLT at each of
the PKC412 dose levels under study was estimated. The next cohort of patients
was administered the dose level at which the estimated probability of DLT was
closest to the 35% threshold DLT rate, provided that the new dose level did not
exceed double the previous dose. The final RD was based on the MTD based
on multiple cycles, since a prolonged administration of PKC412 should be
possible at that dose level.
Pharmacokinetics study
In humans, PKC412 has two main metabolites, the O-demethylation product of
PKC412, CGP62221 (O-desmethyl-N-benzoyl-staurosporine) and 7-hydroxy-
PKC412, referred to as CGP52421 (N-benzoyl-7-hydroxy-staurosporine)
(Figure 1). CGP52421 is a mixture of two epimers (epimer 1, 62.5% of
CGP52421; epimer 2, 37.5% of CGP52421) and has structural homology with
UCN-01 [15]. CGP52421-epimer1 has a short half-life and cannot be meas-
ured in plasma. CGP52421-epimer2 has a long half-life and accumulates over
time [11]. A 24-h PK profile was obtained on day 28 of the first cycle and day
1 of the second cycle, before administering the second cycle of chemotherapy.
Blood samples were collected prior to the first dose and at 1, 2, 4 (prior to the
midday dose), 6, 10 (prior to the evening dose) and 24 h after the first intake.
Blood samples were processed rapidly and protected from light. Samples of
venous blood (3 ml) were collected in heparinized tubes and immediately
centrifuged at 4000 r.p.m. Plasma samples were stored at –20°C until analysis.
Determination of PKC412 and its two main metabolites CGP62221 and
CGP52421-epimer2, in plasma was performed by HPLC with fluorescence
detection. The plasma PKC412 levels were analyzed by Novartis Pharma AG
(Basel, Switzerland) according to published procedures [21]. An Agilent HP
1090 and an Agilent HP1100 HPLC system with a LiChrospher 100 RP18ec,
250 × 4 mm, 5 µm column, protected by the same type of pre-column, were
used. The lowest quantification limit was 75 ng/ml for PKC412, 100 ng/ml for
CGP62221 and 38 ng/ml for CGP52421-epimer2. Non-compartmental
pharmacokinetic parameters were calculated for PKC412 and its metabolites
in order to define the maximum concentration (Cmax) and the area under the
plasma concentration time curve over 24 h (AUC24h) for each dose level, using
the software Turbochrom, versions 6.1.0 and 6.1.2 (Perkin-Elmer, Norwalk,
CT, USA) and Microsoft Excel, version 97 SR-2 (Microsoft, Redmond, WA,
USA).
Results
General
Twenty-four patients with advanced stage IIIB/IV NSCLC entered
the study, including 17 chemotherapy- and radiotherapy-naïve
patients. One patient withdrew his consent before the first PKC412
dose and was not considered evaluable for this study. Character-
istics of the 23 evaluable patients are listed in Table 1.
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None of the four patients included at dose level I experienced
DLT during cycle 1 and consequently dose escalation was
authorized. At dose level II, one of the first four patients included
experienced a grade 3 headache during cycle 1 that disappeared
after discontinuation of PKC412. Four additional patients were
included at dose level II and no other DLT was observed during
the first cycle. Based on the MCRM, the 75 mg/day dose level was
skipped and the 100 mg/day dose was tested as dose level III. At
dose level III, none of the four patients experienced DLT during
cycle 1. At dose level IV, three of four patients had grade 3
diarrhea during cycle 1. For these patients, diarrhea occurred
during the first week of treatment and persisted despite therapy
with loperamide 2 mg given after each stool up to a maximum of
16 mg/day. In each patient, the diarrhea disappeared in <12 h after
discontinuation of PKC412. Two patients were re-challenged
with PKC412 at the same dose and grade 3 diarrhea reappeared
12 h after the first intake. The 150 mg/day PKC412 dose was
therefore considered MTD based on acute toxicity.
At dose level 100 mg/day, three more patients were added to the
four initially included to evaluate toxicities beyond the first cycle.
The last three included patients who experienced prolonged grade
2 or 3 toxicities at cycle two. One patient experienced grade 3
fatigue beginning at day 2 of cycle 2 with grade 3 nausea/vomiting
beginning at day 6 and lasting until discontinuation of PKC412 at
day 10. The second patient experienced grade 2 nausea/vomiting
during cycles 1 and 2; despite intensive anti-emetic regimens,
PKC412 dose reduction (to 50 mg/day) was required at cycle two
without symptom improvement and treatment was interrupted.
The third patient also had long-lasting grade 2 vomiting during
cycles 1 and 2 that disappeared after discontinuation of PKC412 at
day 21 of cycle 2. At dose level 3, the last three patients included
did not differ from the first four patients in terms of PS, metastatic
sites, prior irradiation or concomitant medications. Since 3/7 patients
required treatment discontinuation due to unacceptable toxicity
after repeated cycles, we decided not to include additional patients
at dose level III and this dose level was not considered as meeting
criteria for the RD for phase II studies.
Thus, 50 mg/day, the next dose level tested below 100 mg/day
was considered. In addition to DLT at cycle 1 at 50 mg/day, one
patient had grade 3 nausea/vomiting during the first week of cycle
two that lasted 2 weeks until discontinuation of PKC412. No dose
reduction was performed. As a total of 2/8 patients experienced
PKC412-related DLT at dose level II, the 50 mg/day dose level
was considered as the RD for chronic administration of PKC412
combined with cisplatin and gemcitabine (see Table 2). At this
dose level, PKC412 plasma concentrations were in the range of
the IC50 for preclinical studies. This dose of 50 mg/day was near
Table 1. Patient characteristics
aTwenty-four patients were enrolled, but one patient withdrew 
his consent before administration of PKC412 and was no 
longer further analyzed.
bOne bronchiolo-alveolar carcinoma, one undifferentiated 
carcinoma, five NSCLC not specified further (diagnosis was 
performed by a fine needle biopsy in three patients).
cFor metastatic disease: one chemotherapy line in three 
patients; two chemotherapy lines in one patient.
NSCLC, non-small-cell lung cancer; WHO, World Health 
Organization.
Characteristics No. of patients
Total number of patientsa 23
Gender (male/female) 17/6
Median age, years (range) 56 (39–73)
WHO performance status
0 6
1 11
2 6
Histology of NSCLC
Epidermoid 5
Adenocarcinoma 9
Large cell 2
Othersb 7
Stage of NSCLC
IIIB 5
IV 18
Prior treatment
Chemotherapy onlyc 3
Radiotherapy only 2
Chemotherapyc and radiotherapy 1
No prior therapy 17
Table 2. Number of patients, cycles and DLTs at cycle 1 by PKC412 dose levels
DLT, dose-limiting toxicity; PS, performance status.
Dose level Dose 
(mg/day)
No. of
patients
Patients with 
PS<1
No. of cycles DLTs at cycle 1
Median Range Total No. per patient Types of DLTs
I 25 4 3 5 2–6 18 0/4
II 50 8 6 5 1–6 33 1/8 1 grade 3 headache
III 100 7 5 2 1–4 14 0/7
IV 150 4 3 1 1–1 4 3/4 3 grade 3 diarrhea
Total 23 17 69 4
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the MTD. For several kinase inhibitors the dose recommendation
for phase I trials has been selected based on a compromise
between toxicity, plasma concentrations and surrogate biological
end points of antitumor activity, if any. For PKC412, there was no
clear evidence to support an increase in dose above 50 mg/day in
order to achieve higher activity against PKC enzymes in tumors.
Therefore we decided not to investigate further doses >50 mg/day
and consequently the dose level of 75 mg/day was not explored.
Hematological toxicities
As expected for the cisplatin–gemcitabine regimen, the toxicities
commonly observed were hematological. Cisplatin–gemcitabine-
related hematological toxicities stratified according to PKC412
dose levels are listed in Table 3. Of the 207 scheduled gemcitabine
administrations, dose reduction and omission were necessary in
20% and 29% of cycles, respectively.
At dose level II, among a total of 33 cycles, grade 3–4 neutro-
penia occurred in 2/8 patients. The median ANC nadir was
2.400 × 106/l (range 600–9700 × 106/l). No grade 3–4 neutropenia
lasting >7 days occurred nor was there febrile neutropenia. Grade
3–4 thrombocytopenia occurred in 5/8 patients. The median plate-
let nadir was 60 × 109/l (range 9–491 × 109/l). Only two patients
required platelet transfusions because of grade 4 thrombocyto-
penia. Thrombocytopenia frequently occurred in patients who
received more than two cycles compared with recipients of only
one or two cycle(s), indicating that the cisplatin–gemcitabine
combination may induce cumulative platelet toxicity. Anemia
was usually mild and red blood cell transfusion was not required.
Non-hematological toxicities
Table 4 shows non-hematological toxicities. At dose level II, the
above described DLT was a grade 3 headache at cycle 1. Other
PKC412-related toxicities at the RD were mild to moderate grade
1–2 diarrhea, asthenia/fatigue, headache and prolonged nausea/
vomiting. As mentioned above, one patient had grade 3 nausea/
vomiting that was considered related to PKC412. Other toxicities
were either considered related to cisplatin and/or gemcitabine.
They included grade 2 hearing loss in one patient at level I, grade
1 peripheral neuropathy in two patients at level II, grade 2 anor-
exia in two patients at level I and one patient at level II, grade 2
infections without neutropenia in two patients at level II and one
patient at level IV. Five patients presented cisplatin-related grade
1 elevation of serum creatinine (three patients at dose level II, one
patient at dose level I and one patient at dose level IV).
Activity
Among the 23 patients, 17 (14 chemotherapy naïve) were evalu-
able for tumor response. Three chemotherapy-naïve patients
achieved a partial response, one at dose level I and two at dose
level II. Nine patients had tumor stabilization, which lasted for 4,
5, 7 and 10 months, respectively, in four cases and two of these
four had previously been treated.
Pharmacokinetics
The PKC412 pharmacokinetic profile was assessed in four patients
at the 50 mg dose level. Figure 2 shows the mean plasma concen-
tration–time curves for PKC412, CGP62221 and CGP52421-
epimer2 at dose level II (50 mg/day). At this dose level, the mean
AUC24 of PKC412, CGP62221 and CGP52421-epimer2 was
11389 (range 6447–16739), 17923 (range 10948–25049) and
1513 ng·h/ml (range 1075–1927), respectively. The mean Cmax of
PKC412, CGP62221 and CGP52421-epimer2 was 799 (range
501–1070), 861 (range 569–1189) and 69 (range 47–87) ng/ml,
respectively.
Discussion
Among the PKC inhibitors under clinical development, antisense
oligodeoxynucleotide ISIS-3521 and staurosporine analogues
UCN-01 and PKC412 have been investigated as single agents in
Table 3. Cisplatin–gemcitabine-related hematological toxicity per patient and per cycle
Worst NCI-CTC grades for all courses of PKC412 [17].
G, grade; NCI-CTC, National Cancer Institute-common toxicity criteria.
Daily doses of PKC412 (mg/m2)
25 (n = 4; cycles = 18) 50 (n = 8; cycles = 33) 100 (n = 7; cycles = 14) 150 (n = 4; cycles = 4)
G1–2 G3–4 G1–2 G3–4 G1–2 G3–4 G1–2 G3–4
Neutropenia
Per patient 2 0 1 2 1 2 1 1
Per cycle (%) 2 (11) 0 (0) 9 (27) 5 (15) 1 (7) 3 (21) 1 (25) 1 (25)
Thrombocytopenia
Per patient 1 3 3 5 5 1 2 0
Per cycle (%) 5 (27) 9 (50) 19 (57) 11 (33) 11 (79) 1 (7) 2 (50) 0 (0)
Anemia
Per patient 4 0 8 0 7 0 1 1
Per cycle (%) 17 (94) 0 (0) 31 (94) 0 (0) 11 (79) 0 1 (25) 1 (25)
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patients with advanced malignancies in several phase I/II trials
[10–12]. Schedules, based on laboratory data and selected for
application in clinical studies, have led to prolonged exposure to
PKC inhibitors. ISIS-3521 was given in a 2-h continuous intra-
venous infusion at doses ranging from 0.1 to 6 mg/m2/day three-
times-a-week for 3 consecutive weeks every 4 weeks [1, 12, 22].
Although no DLT was identified, common toxicities such as
nausea/vomiting, fever and chills were reported [12]. UCN-01
was the first staurosporine derivative to be introduced in clinical
trials at a RD of 42.5 mg/m2 given in a 72-h continuous intra-
venous infusion every 4 weeks. DLTs were nausea/vomiting,
symptomatic insulin-resistant hyperglycemia and pulmonary tox-
icity leading to hypoxemia [10].
PKC412 can be administered orally and it provided an oppor-
tunity to explore the effects of prolonged inhibition of PKC during
a clinical trial in patients with advanced cancer. In a previously
published phase I trial, the RD of single agent PKC412 was 150 mg
daily with toxicities consisting of nausea/vomiting, diarrhea and
lethargy/fatigue [11]. In our study, toxicities were either related
to PKC412 or cisplatin–gemcitabine chemotherapy. Diarrhea was
the main DLT of PKC412 when combined with chemotherapy
and prohibited dose escalation >150 mg/day. As gemcitabine and
cisplatin do not induce diarrhea, this toxicity was considered
solely attributable to PKC412. Attempts to control diarrhea with
loperamide were not satisfactory and treatment discontinuation
was required in all patients experiencing diarrhea at a dose level
of 150 mg/day. When re-challenged with PKC412, patients re-
experienced grade 3 diarrhea and this strongly pointed to the role
of PKC412 in this toxicity.
Nausea and vomiting were also frequently documented in our
study and greatly influenced our recommendation for the defin-
ition of MTD and RD. Since PKC412 is given orally for a pro-
longed period of time, discomfort caused by persistent nausea/
vomiting could have an impact on schedule compliance and the
quality of life of patients in future phase II clinical trials. As cis-
platin is also known to induce nausea and vomiting, we proposed
considering grade 2 nausea and vomiting lasting >1 week as a
DLT in our study, in addition to the classic grade 3–4 threshold for
drug-induced DLT. At the dose of 100 mg/day, grade 2–3 nausea/
vomiting lasting >1 week was observed in 3/7 patients who required
treatment discontinuation or dose reduction. The frequency and
severity of nausea/vomiting were also increased in other phase I
studies when PKC412 was combined with paclitaxel and carbo-
platin [23] or protracted infusional 5-fluorouracil [24]. We had no
alternative but to propose the daily dose of 50 mg as the RD in
combination with cisplatin and gemcitabine in our study because
of nausea and vomiting.
From the PKC412 single agent phase I study, we know that
side-effects are dose related and usually occur within the first
week of treatment. PKC isoenzymes are found in every tissue and
the pattern and frequency of toxicities are identical when PKC412
is given as a single agent or in combination [11]. Toxicities, how-
ever, did occur at lower doses of PKC412 and a drug interaction at
the PK level is suspected. However, as PK samples were sched-
uled only at day 28, we cannot confirm this hypothesis, as DLTs
supervene earlier. However, at the pharmacodynamic level, we
should be reminded that PKC412 caused nausea and vomiting as a
single agent and it is not surprising to observe that the addition of
an highly emetic drug such as cisplatin was probably responsible
for the prolonged nausea and vomiting occurring at a much lower
PKC412 dose level.
Table 4. PKC412-related non-hematological toxicity per patient and per cycle
Worst NCI-CTC grades for all courses of PKC412 are reported per patient (no. of patients) and per cycle (no. and percentage of cycles). No grade 4 non-
hematological toxicities occurred during any course. 
aOnly prolonged nausea/vomiting are reported in the table.
G, grade; NCI-CTC, National Cancer Institute-common toxicity criteria.
Daily doses of PKC412 (mg/m2)
25 (n = 4; cycles = 18) 50 (n = 8; cycles = 33) 100 (n = 7; cycles = 14) 150 (n = 4; cycles = 4)
G1–2 G3 G1–2 G3 G1–2 G3 G1–2 G3
Headache
Per patient, n 0 0 2 1 0 0 0 0
Per cycle, n (%) 0 (0) 0 (0) 2 (6) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0)
Diarrhea
Per patient, n 1 0 1 0 2 0 0 3
Per cycle, n (%) 2 (11) 0 (0) 1 (3) 0 (0) 2 (14) 0 (0) 0 (0) 3 (75)
Asthenia/fatigue
Per patient, n 2 0 4 0 1 1 2 0
Per cycle, n (%) 4 (22) 0 (0) 8 (24)  (0) 3 (21) 1 (7) 2 (50) 0 (0)
Prolonged nausea/vomitinga
Per patient, n 0 0 0 1 2 1 0 0
Per cycle, n (%) 0 (0) 0 (0) 0 (0) 1 (3) 4 (29) 1 (7) 0(0) 0 (0)
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In our study, the adjunction of PKC412 had no influence on
cisplatin–gemcitabine-induced hematological toxicity. At a daily
dose of PKC412 50 mg, hematological toxicity was similar in
intensity and frequency to that previously reported with cisplatin–
gemcitabine chemotherapy. With the same schedule of adminis-
tration for the gemcitabine-cisplatin regimen as in our study,
Crinò et al. reported percentages of gemcitabine dose reduction or
omission of 27% and 29%, respectively, compared with 20% and
29% in our phase I trial [25]. Only a larger randomized phase II
trial comparing chemotherapy with and without PKC412 would
allow a better assessment of the toxicities.
The three partial responses and the four long-lasting (>4 months)
tumor stabilizations all occurred at the RD and below. At the RD,
the mean PKC412 Cmax at day 28 was 799 ng/ml (range 501–1070).
The mean plasma PKC412 concentration–time profiles (Figure 2)
at the RD were consistently above the minimal target concentra-
tion required for cytotoxicity in all cell lines, i.e. an inhibitory con-
centration (IC50) of 285 ng/ml (range 114–399). This target
concentration level was reported to exert anti-proliferative and
anti-tumor activity in human tumor models without the presence
of human AAG and it is difficult to be confident of the potential
value of this clinically achieved plasma concentration [26]. How-
ever, previously published data have shown that PKC412 pharmaco-
kinetics are very complex due to the high-affinity protein binding
of PKC412 and its metabolites. In the single-agent PKC412 study,
the linear relationship between the dosage and plasma PKC412
level seen during the first week of treatment disappeared with pro-
longed drug intake. At day 28, no increase was observed in the
plasma PKC412 level with increasing doses ranging from 150 to
300 mg/day. There was accumulation of CGP52421-epimer2, a
10-fold less active metabolite known for its very long elimination
time (median half-life of 36 days; range 27–164 days). CGP52421
has the highest affinity for human AAG (>99.9% binding) due to
its structural homology with UNC-01 [10, 15, 27]. It is possible
that CGP52421-epimer2 displaces PKC412 and CGP62221 from
AAG and that further interaction with cisplatin protein adducts
reinforces this mechanism [28]. Our trial was not designed to test
further these drug interactions. In other studies, attempts were made
to identify biological end points that would correlate with the
biological anti-tumor activity of PKC412. Blood plasma TNF-α
and IL-6 levels and the level of extracellular signal-regulated
kinase 2 using western blotting in peripheral blood mononuclear
cells have been proposed as candidate surrogate end points for
PKC412 [29], but have still not been validated for routine clinical
trials.
In summary, the results of this study indicate that PKC412 at a
dose of 50 mg/day can be safely added to cisplatin–gemcitabine
chemotherapy in patients with advanced NSCLC. The plasma
PKC412 levels achieved at the RD are in the IC50 range of pre-
clinical models without the presence of human AAG. Further
trials are warranted to evaluate the anti-tumor activity of PKC412
in the treatment of advanced NSCLC, either combined with cis-
platin–gemcitabine or with other chemotherapies.
Figure 2. Mean plasma concentration–time profiles of PKC412, CGP62221 and CGP52421-epimer2 at the recommended dose of 50 mg/day.
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